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Summary
Introduction: The bioethical principles of autonomy, beneficence, non-maleficence
and justice, complemented by ethics committee evaluation, define conduct of
clinical trials of anti-epileptic medications (AEM).
Background information: Increased teratogenicity for offspring of women with epi-
lepsy is presented in both lay and scientific literature.
Specific drugs–—older generation: Teratogenicity of phenobarbitone (PB), phenytoin
(PHT), valproate (VPA) and carbamazepine (CBZ) is acknowledged, with drugs, such as
trimethadione, being removed from the market because of teratogenicity.
Specific drugs–—new generation: Insufficient data allowed definitive commentary
concerning teratogenicity of newer AEM, such as lamotrigine (LTG), gabapentin
(GBP), tiagabine (TGB) or levetiracetam (LEV). All those suggestions favour some
over others with specific AEM combinations being questioned.
Pregnancy registries: Lack of information sporn AEM-specific plus national and
international birth registries which endorse VPA, CBZ and LTG dose related concerns.
Conflict of interest: Competing influences of AEM and epilepsy-specific factors need
delineation although appear more teratogenetic than does epilepsy alone.
Clinical trials: Most trials focus upon refractory epilepsy with potentially enhanced
risks. Informed consent demands discussion of possible teratogenicity and exclusion of
women unwilling to practice adequate contraception.
Discussion: Trials must respect legal and ethical dictates including the exclusion of
women unwilling to practice reliable contraception. Automatic exclusion from a
trial, subsequent to confirmed pregnancy, is unlikely to protect the foetus as
potential for teratogenicity already has occurred. Autonomy should empower* Tel.: +61 2 9415 3800; fax: +61 2 9413 1353.
E-mail address: roy.beran@unsw.edu.au.
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prospective parents to decide continued trial participation consequent to detailed
informed consent without coercion. All options demand review, including respon-
sibility to future AEM users.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Contents
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
General background information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 564
Specific drugs–—older generation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
Specific drugs–—new generation of AEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
Pregnancy registers in epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 565
Conflict of opinion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
Clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 566
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 569Introduction
‘‘. . . Prudence, temperance, justice and courage are
often named as the four cardinal virtues from the
writings of Plato and Aristotle, and faith, hope, and
charity, as those of modern theological writings
. . .’’.1 Despite this theological backdrop, practical
wisdom must play an integral component within the
debate regarding ethical considerations concerning
health care delivery.2 More than a decade ago,
Beauchamp and Childress, American ethicists who
adopted different ethical paradigms, one a utilitar-
ian and the other a deontologist, agreed that the
four basic principles of bioethics should be: auton-
omy, beneficence, non-maleficence, and justice.3
This endorsed and reinforced the views of the British
doctor and ethicist, Gillon, from a decade earlier
with these basic tenets described as: beneficence,
non-maleficence, respect for autonomy and justice.4
Simply put, these concepts are: respect for an
individual’s right for self-determination; the princi-
ple of ‘doing good’ and offering the best of care with
respect for duty of care; avoiding doing harm if
practicable or alternatively minimising any harm
to be encountered; and a proper distribution of
the benefit to burden ratio which aims at achieving
optimal outcomes. One of the safeguards, designed
to protect this balance of potentially conflicting
expectations, is the use of an intermediary in the
form of a Human Research Ethics Committee
(HREC). The role of the HREC has been adopted
and incorporated into the conduct of clinical
research which must respect ethical issues.1 Rever-
end Little5 has eloquently demonstrated his percep-
tions of the pressures imposed by researchers in
their search for novel and more efficacious treat-
ments as contrasted with the evaluation of the risksto which the individual subjects can or should be
exposed.
It is apparent that the proper balance of ethical
considerations needs to be the primary concern for
any investigator who is involved in clinical research.
Even allowing for the incorporation of an HREC,
within this process, does not eliminate the need
for in-depth reflection by all concerned in clinical
research, particularly if that involves human sub-
jects.
Such deliberation was the motivating force driv-
ing the arguments and developments contained
within this paper which focuses upon the inclusion
of pregnant women within clinical trials of anti-
epileptic medications (AEMs). What follows is a
review of the existing knowledge as a foundation
upon which to consider such inclusion.General background information
Standard textbooks which review the relationship of
women and epilepsy6—8 acknowledge the increased
risk of teratogenicity for the offspring of women
with epilepsy whether they are, or are not, on
medication. Double the rate of major malformations
is acknowledged for children born to mothers with
epilepsy9 as is a similar increase in minor abnorm-
alities.9 Information sheets posted on the internet
indicate that there is a 1.5—2% increase of signifi-
cant abnormality at birth if the women has epilepsy,
even if she is seizure-free and off medication during
the pregnancy, over women in the general popula-
tion. This same website goes on to say ‘‘. . . status
epilepticus . . . is . . . potentially fatal for bothmother
and child . . . This is why women with epilepsy dis-
covering themselves to be unexpectedly pregnant
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The same source of public information cites the risk
of abnormality in the children born to women with
epilepsy as increasing from 4 to 7% if the mother is
taking a single AEM at the time of conception.10 This
rises to 15% if she is on two AEMs (with some AEM
combinations leading to a 50% risk).10 This threat is
maximal in the first 56 days of gestation6,10 with the
danger after 4 months gestation thought to be very
low.10 The web-page emphasises that, ‘‘. . . the dan-
ger period starts before the woman knows she is
pregnant . . .’’.10
Broad commentary regarding increased risk of
malformation in the offspring of mothers with epi-
lepsy is not restricted to lay publications11—13
although Holmes et al.13 did not find a higher fre-
quency of abnormalities in the 98 infants born to
mothers with epilepsy who were not taking AEMs as
compared with the general population. Holmes
et al.13 did find an increase inmalformations reflect-
ing the number of AEMs being taken by the mother
thereby confirming earlier data from Kaneko et al.14
Morrell15 suggested that reliance on polyphar-
macy, with multiple AEMs, may be indicative of
more difficult to manage epilepsy thereby suggest-
ing that the increased risk of malformation may be
multifactorial thus questioning an epilepsy-specific
factor. It could reflect the severity of the epilepsy,
drug-to-drug interactions, increased induction of
the cytrochrome P450 system in the liver, increased
effects of AEM metabolites or simply the nature of
the epilepsy itself.15 The role of folate as a protec-
tive agent, especially with regards to neural tube
defects, remains to be confirmed.16Specific drugs–—older generation
Fear of gestational effects of specific AEMs is not
new. Melchior et al. examined the placental transfer
of phenobarbitone (PB) almost four decades ago.17
PB teratogenicity has been well recognised for many
years.18 The foetal hydantoin syndrome, as may be
associated with the use of phenytoin (PHT), was well
recognised over three decades ago.17—24
The prospect of foetopathy has actually led to the
removal of specific AEMs from the marketplace.
Perhaps the most memorable of these has been
the rise and fall of trimethadione.25—27 The ‘‘tri-
methadione syndrome’’ included deformities of cra-
niofacies, cardiovascular system, trunk, neck,
urogenital system and skeletal system.28
By the 1980’s sodium valproate (VPA) was well
recognised as a cause of foetopathy, particularly
with regards to neural tube defects.29—34 Around
this same time carbamazepine (CBZ) was alsoattracting attention for its capacity to cause birth
defects, including neural tube defects.35,36
There remains conflicting data which suggests
that drugs such as CBZ, oxcarbazepine (OXC) and
PHT do not pose increased risk of malformation
which is largely restricted to VPA.37 Other studies
have impugned specific AEM combinations such as
VPA plus CBZ or PHTwith primidone (PRM) plus PB.14Specific drugs–—new generation of AEM
Of the newer generation of AEMs, lamotrigine (LTG)
has been investigated and deemed to be much safer
than are the older generation of AEM,38,39 especially
with exposure in the first trimester. Much of the data
relative to the newer AEMs are too brief to draw any
real conclusions.
A perfect example of this is the 27 pregnancies
encountered in clinical trials with tiagabine (TGB)
although even based on these small data there
appears an increase of problems in the offspring
of women treated with TGB.40
Similarly the finding of no adverse events from 11
pregnancies amongst women on gabapentin (GBP)
are too few to allow any concrete conclusions
although on these tiny numbers it would appear
that GPB is safer than is TGB.41 The report of 51
pregnancies involving GBP is still too small to draw
any hard and fast opinions although the data do
suggest rates of perinatal problems and malforma-
tions to be less than, or similar to, those encoun-
tered in the general population or in women with
epilepsy not on treatment.42
Equally small and essentially non-interpretable
data are provided for other newer generation AEM,
such as levetiracetam (LEV).43 Of the 23 pregnancies
reported with LEV, a third (nine) resulted in healthy
offspring for 8 women (one, on combination of LEV
and PHT, had twins). Awoman on the combination of
LEV-CBZ-PB gave birth to a child with tetralogy of
Fallot.43 What this case reveals is that it is impos-
sible to discern which of the AEMs was responsible, if
any were, for such a malformation.Pregnancy registers in epilepsy
Acknowledging that small numbers of patients
result in inconclusive data, there has been a
push to develop specific AEM registries as well
as national and international birth regis-
tries.38,39,42,44—50 It is still too early to make any
definitive commentary regarding the newer AEM
although the findings of many of the registries echo
data that has been known for some time, namely
566 R.G. Beranthat under therapeutic conditions VPA may be
regarded as considerably teratogenic and all other
AEM are weakly so.38,49,51 More recent information
has identified a dose relationship with malforma-
tions with LTG and CBZ in addition to VPA.52Conflict of opinion
Concurrent with this debate regarding the effects of
specific medications, the role of epilepsy itself, as a
cause of teratogenicity, is still being explored.24,53
Even the relatives of those with epilepsy have been
assessed for malformations.54
As has already been stated, both in the lay lit-
erature and in the scientific press, it is still not
certain that the AEMs are the sole cause for foeto-
pathy in the offspring of women with epilepsy. It is
accepted that the choice of AEM is dictated by the
type of epilepsy. VPA remains the principal choice
for the treatment of generalised epilepsy and hence
one cannot totally exclude the possibility that some
maternal epilepsy related characteristic may pre-
dispose these offspring to malformation or devel-
opmental problems.16
It is also argued that tonic—clonic status epilep-
ticus may evoke very serious consequences for the
foetal brain.55 There is also a suggestion that partial
seizures, with focal epilepsy, may cause negative
consequences for the foetus.56 Affects on the foetus
are not restricted to brain function during convul-
sive seizures, cardiac consequences have been
reported.57 Convulsive seizures have been shown
to cause lactic acidosis, the consequences of which
are unclear for the foetus.58
Previous research suggested that maternal sei-
zures, occurring during pregnancy, did have an
association with increased risk of specific cognitive
dysfunction.59 More recently there have been
reports that the experience of five or more convul-
sive seizures, during pregnancy, was associated with
an increase in cognitive dysfunction for verbal intel-
ligence.60
Single case reports have also identified issues
such as intracranial haemorrhage in utero as a con-
sequence of nocturnal seizures.61 Others have
attempted to review these questions, regarding
the effects of seizures, with inconclusive findings.13
Hauser and Hesdorffer, in a comprehensive review of
the epidemiological data wrote, ‘‘. . . It is unclear
whether seizures or anti-epileptic drugs are asso-
ciated with defect among offspring . . .’’.28 They
further reviewed the data to show that malforma-
tions for the offspring born to women who had
seizures during pregnancy were higher whether or
not thewomenwere treatedwith AEM, although thisfigure was significantly increased where AEMs were
prescribed.28Clinical trials
Subjects recruited for inclusion into clinical trials
represent those in whom current therapies have
either been inadequate or preferable option in de
novo patients. Initial trials used add-on methodol-
ogies, usually with randomised controlled protocols.
Only with proof of concept are de novo studies
contemplated and only then if it is seriously antici-
pated that the experimental AEM may offer a better
option.
Guidelines for Good Clinical Practice (GCP) dic-
tate that patients should be advised of potential
reproductive toxicity and mutagenicity as is known
at the time of the study.62 In accordance with GCP it
is the investigator’s responsibility to gain informed
consent to undertake the study with each patient/
subject being fully informed, including ‘‘. . . The
reasonably foreseeable risks of or inconveniences
to the subject and, when applicable, to an embryo,
foetus or nursing infant . . .’’.63
GCP also requires that the investigator must
advise each subject of ‘‘. . . The foreseeable circum-
stances and/or reasons under which the subject’s
participation in the trial may be terminated . . .’’.63
The Helsinki Declaration64 enshrines the ethical
ethos of protecting the patient, namely non-malefi-
cence and beneficence. It essentially codifies the
concepts cited above in the introductory discussion
of ethics.
It has long been accepted that there may well be
conflict between ethical and legal considerations
within any given set of circumstances and this is
particularly apparent within the concept of clinical
drug trials.65 Where such conflict exists, the
National Health and Medical Research Council (NH
& MRC) guidelines confirm that the researcher
should respect the legal demands.66 The NH &
MRC guidelines go on to say that where ethical
expectations eclipse minimal legal standard then
researchers should venerate those higher principles
which still recognise legal demands.66Discussion
The information which is set out above has estab-
lished the framework within which to consider the
involvement of pregnant women within clinical
trials of new AEMs.1—66 One should never lose sight
of the need to behave in an ethical manner within
the boundaries defined both in the introductory
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eficence, non-maleficence and justice, as well as
respect for the principles set out in the section
dealing with clinical trials.62—66
Concurrent with these foundations of ethical
behaviour one must not ignore legal obligations to
protect both the women with epilepsy and her
prospective offspring.65,66 GCP and investigator
obligations62—64 demand that women who are fertile
and at risk of consequences of exposure to experi-
mental AEMs must be warned of the risks posed to
pregnancy. This clearly translates into discussion of
potential teratogenicity. It follows that non-malefi-
cence would support the exclusion of such women
from recruitment to clinical trials if they are not
prepared to practice effective contraception.
There cannot be debate that what amounts to
considerable ignorance of the potential for terato-
genicity38—51,55—61 places the mother and offspring
at inherent risk of malformation, or subtle defects,
which could best be averted by preventing a preg-
nancy occurring during the time of exposure to an
experimental agent. While drug interactions
between AEMs has been considered15 it most likely
would be impossible to totally exclude the capacity
for there also to be an interaction between an
experimental AEM and the oral contraceptive hor-
mone pill.67 Thus conceivable failure of contracep-
tion should also be discussed prior to obtaining
informed consent for a potentially fertile woman
to be recruited into a trial. Non-maleficence
requires that these issues be openly addressed
and the subject given every opportunity to decline
entry into the trial.
It is hard to conceive of a situation where poten-
tial for pregnancy, within a clinical trial of an
experimental AEM, is openly encouraged prior to
recruitment. The debate to follow recognises this
position. It endorses the posture of actively dis-
couraging women who are wanting to become preg-
nant, or who either are pregnant or breastfeeding,
from inclusion within such studies. It is accepted
that such circumstances constitute valid grounds for
exclusion from recruitment into trials of experimen-
tal AEMs.
The divergence occurs and the wrangle emerges
for female subjects, who clearly understood the
inherent risks, agreed to practice adequate contra-
ception prior to inclusion into the study but who still
became pregnant while within the trial. The fact
that the female subject understood the fundamen-
tal dangers is encapsulated in her signing of the
informed consent, presumably after full consulta-
tion and provision of HREC approved documentation
outlining both the uncertainty and the basis for
consent.65 The whole tenet of such procedures isto guarantee that the inclusion of women of poten-
tial childbearing capacity are advised of the possible
hazards within a relative vacuum of knowledge to
ensure that they do not become pregnant.
As has already been stated, those patients
included within clinical trials of AEM are usually
those patients with more difficult to manage and
poorly controlled epilepsy, in whom the experimen-
tal AEM is often added to one or more of the existing
AEM already taken by the patient. The information
provided has demonstrated that the chance for
teratogenicity increases with polypharmacy10,13—
15,28 and thus it is highly probable that add-on
clinical trials of AEM amplify the opportunity for
malformations.
It is also apparent that those who satisfy inclusion
criteria have been selected because of their difficult
to control epilepsy. This translates into an increased
intrinsic propensity for seizures to occur during
pregnancy. The data provided have suggested that
such seizures, especially convulsive episodes or
even worse, status epilepticus, do carry imminent
ability to adversely affect the foetus.10,15,55,57—61
This assumes increased relevance for the woman
who has achieved seizure control, as a consequence
of exposure to an experimental AEM whilst in a trial,
and who has subsequently become pregnant but in
whom the sponsor may demand immediate with-
drawal from study medication. It is acknowledged
that it is possible that a patient has become seizure-
free while in the placebo arm of a comparative trial
but if this were to be the case then no ethical issue
emerges as it is assumed that the placebo is inert.
Withdrawal, consequent to effective intervention,
would undoubtedly enhance risk of seizures during
the pregnancy10 and the possibility of status epilep-
ticus,10 with possible serious adverse consequence
to the foetus,10,55,56,59—61 which cannot be ignored.
Parallel with this argument is the capacity for
experimental AEM to interact with existing AEM
thereby both compounding and confounding the
possibility of malformations in the offspring. One
should also not ignore the risk of instability to
seizure control following withdrawal of medications
within the context of potential interactions. There
may be both pharmacokinetic and pharmodynamic
effects on both the epilepsy and the patient. Were
there unequivocal answers to these issues then
there would be little need to conduct the type of
clinical trial being undertaken. It follows that there
cannot be clear knowledge of the repercussions that
may ensue following withdrawal of an experimental
AEM within this context.
It has already been demonstrated that long estab-
lished AEMs have teratogenicity17—38 and it is the
lack of experience with the newer AEMs, within the
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there is no definitive answer to their potential for
harm.39—47 It is arguable that there is no real dif-
ference to the clinical use of a new AEM in open
clinical practice, as compared with its use in clinical
trials, namely that ethical conduct requires the
clinician to actively warn the woman against becom-
ing pregnant, essentially because of a lack of knowl-
edge about potential teratogenicity.62—66 This
position has been reinforced within trial protocol
which positively excludes patients as part of the
study design who want to become, or who are,
pregnant or breastfeeding. Where the debate
emerges is the prospect of denial of autonomy
and justice that ensues for the woman who has
inadvertently become pregnant while already par-
ticipating within the conduct of a trial. Exclusion
from further participation in the trial removes her
capacity to decide her own future and that of her
unborn child.
By the time that the woman discovers that she is
pregnant, she is well into, or even through, the first
trimester of the pregnancy. The above data has
suggested that the first 56 days translate into the
maximal risk for the foetus10,28 and hence, by the
time the woman knows she is pregnant, the foetal
consequences have most likely already occurred.
Thus denial of access to further experimental AEM
is unlikely to protect the foetus which has already
been exposed. One could argue that the fate of the
pregnancy has already been determined by the time
the pregnancy has been confirmed. Within this con-
text one should respect the wishes of the mother
and father of the unborn child.
The imposition of immediate withdrawal from
the experimental AEM may not represent the opti-
mal decision. There are a number of alternatives
which should be canvassed, such as elective termi-
nation of the pregnancy; continuation of the experi-
mental AEM and the realisation of the birth based on
the current regimen; maintenance of the pregnancy
without further exposure to the experimental AEM;
or in those cases where the experimental AEM has
achieved previously unachievable seizure-freedom,
withdrawal of other AEMs, with proven teratogeni-
city, while continuing monotherapy with the experi-
mental AEM.
The autonomy of the experimental subject would
demand that the patient has the right for informed
self-determination in which she, plus her partner,
make the decision based on the best advice which
the investigator and/or sponsor, of the trial can
offer. To force a decision upon the subject is to
deny the basis of willingness to be a subject within
a trial, namely that of informed consent which is
based on the best available information. For thesponsor of a trial to claim legal imperative of duty of
care to exclude the patient from further exposure to
the experimental AEM is also to deny both autonomy
and the very likely scenario that if damage is to
occur it has already happened.
It is imperative to reiterate that it is not only
acceptable but also advisable to actively dissuade
potentially pregnant women from participating
within clinical trials of AEM.62—66 Some may argue
that even such exclusion is debatable but protection
of the potential offspring, in the face of possible
harm, remains mandatory from the perspective of
the non-malevolence principle. Conversely, once
the female subject is aware of her pregnancy, such
protection has been obviated and the principles of
autonomy and self-determination and justice
assume priority. Under these considerations the
female patient who is pregnant deserves the right
to provide informed decision-making in the light of
all available information rather than having such
right usurped by those who are conducting the trial.
It must be recognised that initial warning of poten-
tial risks of pregnancy should have been part of the
original informed consent to participate in the trial.
There is no argument proffered to restrict exclusion
of such candidates from recruitment into such trials
if only on the basis of non-maleficence. What is
proposed is to empower women who have inadver-
tently become pregnant, while participating within
such a trial, to decide how they would like to
proceed. This paper argues forcefully that it is
inappropriate to automatically impose exclusion
from the trial for such patients should they, upon
full and comprehensive reflection, elect to continue
within the protocol.
A final issue for consideration regarding the invo-
luntary removal of such subjects from clinical trials,
is the question of the ethical obligations for future
women who may later be exposed to the AEM. Once
experimental trials have concluded and the AEM is
freely available to the general population there will
be absolutely no data with which to advise prospec-
tive patients. Such availability of the new AEM will
occur within a virtual vacuum of knowledge and
merely postpone the inevitable, as was encountered
with trimethadione,25—28 should the experimental
AEM pose unacceptable risks. At no time will a
pregnancy be more closely scrutinised or monitored
than will happen within the rigorous dictates of a
clinical trial. Such scrutiny may offer a unique
opportunity to better understand pharmacokinetic,
physiological and pharmacological interactions
should the subject elect to continue within a trial,
consequent to full disclosure and informed consent.
It could be suggested that such pregnancies,
while representing unequivocal protocol violations,
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elect following further informed consent. They
should be monitored with the most stringent pre-
determined protocol procedures if the prospective
parents elect to continue with the pregnancy under
the aegis of the clinical trial. Such policy would
allow patient autonomy while at the same time
respecting the utilitarian ethical paradigm which
strives for the greatest good for the most people.
It must be emphasised that this is only practical if
there is absolutely no hint of coercion, within the
decision-making process, for the prospective par-
ents to continue within the trial.
In conclusion, this debate would suggest that it is
unethical to unilaterally enforce withdrawal of
women who become pregnant while participating
within clinical trials of experimental AEM. They both
deserve and require full and open discussion of all
the known facts to respect their autonomy in the
decision-making process. At no time should there be
consideration of anything other than their best
interests, such that beneficence is respected, and
there should never be coercion to continue with a
trial against a subject’s wishes. Justice demands
that women who become pregnant within clinical
trials have the right to decide their own future
because the data are insufficiently clear to make
an absolute decision to overcome any concept of
non-maleficence once the pregnancy has been con-
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